BAYER AG NA O.N.
Commented by Armin Schulz on June 26th, 2023 | 09:20 CEST
Bayer, BioNxt Solutions, BioNTech - Biotech facing a rebound?
Due to the Corona pandemic, the pharmaceutical and biotech sector received a lot of attention. Many investors invested too late and could hardly benefit from the significant upward movements. After the hype, a sense of disillusionment set in. The vaccine manufacturers felt the effects because as soon as the pandemic subsided, the stock market also went down. Large and small companies experienced sell-offs, with some trading below their cash reserves. These low prices led to a wave of takeovers. Most recently, Novartis snapped up the biotech company Chinook for up to USD 3.5 billion. Therefore, today, we look at three companies from the healthcare sector.
Read
Commented by Juliane Zielonka on June 9th, 2023 | 07:30 CEST
Defence Therapeutics, Bayer AG, Palantir Technologies - Networked data revolutionizes the future of production
In the battle against cancer, the Canadian biotech company Defence Therapeutics is focusing on pancreatic cancer cells. They are currently conducting a new study that aims to develop a vaccination against pancreatic cancer. A crucial factor driving this project is the utilization of networked data. Bayer AG is also active in Canada. The Company is partnering with Acuitas to develop new business areas in the field of mRNA-based gene therapy. Palantir Technologies' move to become active in the energy sector is also new. A battery plant in North America serves as a sandbox for this. We provide insight into the latest developments for investors with a growth strategy.
Read
Commented by Fabian Lorenz on June 7th, 2023 | 08:00 CEST
Commodity shares with price potential: Bayer, K+S, and Almonty Industries in the analyst check
There are no signs of a deep recession in the US at the moment, which is positive for commodity prices and the corresponding companies. What do analysts say? They see a price potential of over 170% for tungsten producer Almonty Industries. With the commissioning of the flagship mine in South Korea, revenues and profits should increase strongly from 2024. After K+S earned brilliantly last year, there is a lack of positive impulses this year. Several analysts have spoken out. Can the DAX-listed company make gains again? At Bayer, the euphoria surrounding the change in the board of directors has faded, and the share price is almost back to where it was at the beginning of the year. But analysts see significant upside potential.
Read
Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST
BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns
Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.
Read
Commented by André Will-Laudien on May 16th, 2023 | 09:45 CEST
BioNTech, Bayer, BioNxt, Formycon - The next biotech wave is rolling in - select carefully now!
Even after Corona, the biotech sector remains an interesting investment sector because it is still important to keep an eye on the major widespread diseases. For many companies, this will probably mean a longer waiting game for investors. In addition to the promising research approaches and milestone plans, the cash reserves of these companies are also important. While having ample funding can lead to quick progress in the laboratory, it is crucial to have the necessary liquidity. In refinancing, however, things have become a little frostier since the rise in interest rates. Which companies should be put under the microscope?
Read
Commented by Juliane Zielonka on May 4th, 2023 | 08:50 CEST
Bayer AG, First Phosphate, Porsche - In the fast lane with the right stock mix
Can sustainability and profitability go hand in hand? When looking at First Phosphate, a company that recently went public, this is true. The Company has found its place in the niche of LFP batteries for the global energy transition. Porsche AG also knows that electromobility is winning the race. The eMacan is selling so well that CFO Meschke has set a target return of 19%. Is that what Bayer's new CEO, Bill Anderson, is thinking? The conglomerate of Consumer Health, Crop Science and Pharma has more potential than the market is currently pricing in.
Read
Commented by Fabian Lorenz on May 3rd, 2023 | 07:30 CEST
Starting signal for a share price rally? BioNTech, Bayer, and BioNxt Solutions ahead of important dates
Things can move fast in the biotech sector. The share price of Prometheus Biosciences shot up by a good 75% practically overnight. The reason: US pharmaceutical group Merck & Co wants to buy the Company specializing in treating immune diseases, thus strengthening its own product portfolio. Thanks to clever takeovers, Sartorius has also grown strongly in recent years, become a success story on the German stock market and risen to the DAX. The latest acquisition of the laboratory supplier is Polyplus. The French company develops DNA and RNA components for cell and gene therapies. Is BioNxt, also active in Germany, the next takeover candidate? In any case, the Company is taking big steps towards commercialization. Investors are also hoping for new impetus from Bayer and BioNTech. Both companies have important dates coming up. But analysts are skeptical.
Read
Commented by Juliane Zielonka on April 19th, 2023 | 11:20 CEST
BioNxt Solutions, Bayer, Morphosys - Using high-speed technology to beat cancer in men
Cancer drugs dominate the global pharmaceutical market and register a significant share. While the global market was worth around EUR 128.6 billion in 2019, it is expected to be around EUR 159.3 billion in 2022. This is reason enough for pharmaceutical companies such as Bayer and Morphosys to advance their research in these areas. Men are particularly affected by specific types of cancer. But what good is the best therapeutic agent if the effect is not achieved immediately? This is precisely where BioNxt Solutions comes in, with a unique coating technology for the rapid release of active substances.
Read
Commented by Juliane Zielonka on April 14th, 2023 | 10:23 CEST
Bayer, Defence Therapeutics, Merck KGaA - Data power ensures high-speed commercialization
Germany is one of the best-funded countries in terms of research-based pharmaceutical companies. Nevertheless, Stefan Oelrich of Bayer Healthcare is critical. He thinks that data protection is putting the brakes on research. Defence Therapeutics, on the other hand, relies on enormous speed. Thanks to their data-driven ACCUM™ platform technology, they are helping mRNA vaccines, in particular, to achieve more intensive results. Pharmaceutical giant Merck is currently experiencing just how valuable data is in the US. In a Phase III clinical trial, the FDA stopped the enrolment of further patients, thus slowing down the research. The reason for the stop, however, is a serious one...
Read
Commented by André Will-Laudien on April 12th, 2023 | 10:34 CEST
Attention, biotech is back! Bayer, Defence Therapeutics, BioNTech - These stocks are breaking out!
For months the market did not care about biotech stocks. But now technical bottoms have been reached, and a rise is likely. In this context, the capital market interest rate is important: if it falls due to increased fears of recession, there is no stopping the biotechs because refinancing costs fall. Sentiment measurements over Easter showed that the risk bias of investors has also returned. If not now, then when, the moment is favorable! Shortlist the following stocks.
Read